Adalimumab: Adalimumab is a fully human monoclonal antibody with a high binding specificity against TNF-α; it was first used for rheumatoid arthritis and psoriatic arthritis. It is FDA-approved for the treatment of adults and children aged four years and older with moderate-to-severe chronic plaque psoriasis. The gene discussed is TNF; the disease is psoriatic arthritis.